Look at Total Prescribing Information OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed soon after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or just after three or maybe more lines of systemic therapy that features